Sunil Agarwal - 23 Jan 2026 Form 4 Insider Report for Astria Therapeutics, Inc. (ATXS)

Reporting relationship: Director
Issuer ticker: ATXS
Reported as of: 23 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2026, 16:15:41 UTC
Prior SEC filing: 30 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Ben Harshbarger, as attorney-in-fact for Sunil Agarwal

Key filing fact

Sunil Agarwal filed Form 4 for Astria Therapeutics, Inc. (ATXS) on 23 Jan 2026.

Key facts

This page summarizes Sunil Agarwal's Form 4 filing for Astria Therapeutics, Inc. (ATXS).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Jan 2026, 16:15.

Change

Previous filing in this sequence was filed on 30 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001616640 Primary reporting owner

AGARWAL SUNIL

Relationship: Director
Address: C/O ASTRIA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 10TH FLOOR, BOSTON
Signature: /s/ Ben Harshbarger, as attorney-in-fact for Sunil Agarwal
Signature date: 23 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATXS transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -28,200
Change %: -100%
Price
Shares after: 0
Date: 23 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,200
Exercise price: $11.40
Footnotes: F1

ATXS transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -26,550
Change %: -100%
Price
Shares after: 0
Date: 23 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,550
Exercise price: $5.79
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Sunil Agarwal is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.